RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

Matthew J. Niederst, Lecia V. Sequist, John T. Poirier, Craig H. Mermel, Elizabeth L. Lockerman, Angel R. Garcia, Ryohei Katayama, Carlotta Costa, Kenneth N. Ross, Teresa Moran, Emily Howe, Linnea E. Fulton, Hillary E. Mulvey, Lindsay A. Bernardo, Farhiya Mohamoud, Norikatsu Miyoshi, Paul A. VanderLaan, Daniel B. Costa, Pasi A. Jänne, Darrell R. BorgerSridhar Ramaswamy, Toshi Shioda, Anthony J. Iafrate, Gad Getz, Charles M. Rudin, Mari Mino-Kenudson, Jeffrey A. Engelman

Research output: Contribution to journalArticle

Abstract

Tyrosine kinase inhibitors are effective treatments for non-small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations. However, relapse typically occurs after an average of 1 year of continuous treatment. A fundamental histological transformation from NSCLC to small-cell lung cancer (SCLC) is observed in a subset of the resistant cancers, but the molecular changes associated with this transformation remain unknown. Analysis of tumour samples and cell lines derived from resistant EGFR mutant patients revealed that Retinoblastoma (RB) is lost in 100% of these SCLC transformed cases, but rarely in those that remain NSCLC. Further, increased neuroendocrine marker and decreased EGFR expression as well as greater sensitivity to BCL2 family inhibition are observed in resistant SCLC transformed cancers compared with resistant NSCLCs. Together, these findings suggest that this subset of resistant cancers ultimately adopt many of the molecular and phenotypic characteristics of classical SCLC.

Original languageEnglish (US)
Article number6377
JournalNature Communications
Volume6
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Retinoblastoma
Small Cell Lung Carcinoma
Epidermal Growth Factor Receptor
Non-Small Cell Lung Carcinoma
lungs
cancer
Cells
Neoplasms
Protein-Tyrosine Kinases
Tumors
Tumor Cell Line
set theory
Recurrence
Mutation
Adenocarcinoma of lung
Therapeutics
tyrosine
mutations
cultured cells
markers

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Chemistry(all)
  • Physics and Astronomy(all)

Cite this

Niederst, M. J., Sequist, L. V., Poirier, J. T., Mermel, C. H., Lockerman, E. L., Garcia, A. R., ... Engelman, J. A. (2015). RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nature Communications, 6, [6377]. https://doi.org/10.1038/ncomms7377

RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. / Niederst, Matthew J.; Sequist, Lecia V.; Poirier, John T.; Mermel, Craig H.; Lockerman, Elizabeth L.; Garcia, Angel R.; Katayama, Ryohei; Costa, Carlotta; Ross, Kenneth N.; Moran, Teresa; Howe, Emily; Fulton, Linnea E.; Mulvey, Hillary E.; Bernardo, Lindsay A.; Mohamoud, Farhiya; Miyoshi, Norikatsu; VanderLaan, Paul A.; Costa, Daniel B.; Jänne, Pasi A.; Borger, Darrell R.; Ramaswamy, Sridhar; Shioda, Toshi; Iafrate, Anthony J.; Getz, Gad; Rudin, Charles M.; Mino-Kenudson, Mari; Engelman, Jeffrey A.

In: Nature Communications, Vol. 6, 6377, 2015.

Research output: Contribution to journalArticle

Niederst, MJ, Sequist, LV, Poirier, JT, Mermel, CH, Lockerman, EL, Garcia, AR, Katayama, R, Costa, C, Ross, KN, Moran, T, Howe, E, Fulton, LE, Mulvey, HE, Bernardo, LA, Mohamoud, F, Miyoshi, N, VanderLaan, PA, Costa, DB, Jänne, PA, Borger, DR, Ramaswamy, S, Shioda, T, Iafrate, AJ, Getz, G, Rudin, CM, Mino-Kenudson, M & Engelman, JA 2015, 'RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer', Nature Communications, vol. 6, 6377. https://doi.org/10.1038/ncomms7377
Niederst, Matthew J. ; Sequist, Lecia V. ; Poirier, John T. ; Mermel, Craig H. ; Lockerman, Elizabeth L. ; Garcia, Angel R. ; Katayama, Ryohei ; Costa, Carlotta ; Ross, Kenneth N. ; Moran, Teresa ; Howe, Emily ; Fulton, Linnea E. ; Mulvey, Hillary E. ; Bernardo, Lindsay A. ; Mohamoud, Farhiya ; Miyoshi, Norikatsu ; VanderLaan, Paul A. ; Costa, Daniel B. ; Jänne, Pasi A. ; Borger, Darrell R. ; Ramaswamy, Sridhar ; Shioda, Toshi ; Iafrate, Anthony J. ; Getz, Gad ; Rudin, Charles M. ; Mino-Kenudson, Mari ; Engelman, Jeffrey A. / RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. In: Nature Communications. 2015 ; Vol. 6.
@article{a380a915b0824f55bc36fc00903c8545,
title = "RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer",
abstract = "Tyrosine kinase inhibitors are effective treatments for non-small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations. However, relapse typically occurs after an average of 1 year of continuous treatment. A fundamental histological transformation from NSCLC to small-cell lung cancer (SCLC) is observed in a subset of the resistant cancers, but the molecular changes associated with this transformation remain unknown. Analysis of tumour samples and cell lines derived from resistant EGFR mutant patients revealed that Retinoblastoma (RB) is lost in 100{\%} of these SCLC transformed cases, but rarely in those that remain NSCLC. Further, increased neuroendocrine marker and decreased EGFR expression as well as greater sensitivity to BCL2 family inhibition are observed in resistant SCLC transformed cancers compared with resistant NSCLCs. Together, these findings suggest that this subset of resistant cancers ultimately adopt many of the molecular and phenotypic characteristics of classical SCLC.",
author = "Niederst, {Matthew J.} and Sequist, {Lecia V.} and Poirier, {John T.} and Mermel, {Craig H.} and Lockerman, {Elizabeth L.} and Garcia, {Angel R.} and Ryohei Katayama and Carlotta Costa and Ross, {Kenneth N.} and Teresa Moran and Emily Howe and Fulton, {Linnea E.} and Mulvey, {Hillary E.} and Bernardo, {Lindsay A.} and Farhiya Mohamoud and Norikatsu Miyoshi and VanderLaan, {Paul A.} and Costa, {Daniel B.} and J{\"a}nne, {Pasi A.} and Borger, {Darrell R.} and Sridhar Ramaswamy and Toshi Shioda and Iafrate, {Anthony J.} and Gad Getz and Rudin, {Charles M.} and Mari Mino-Kenudson and Engelman, {Jeffrey A.}",
year = "2015",
doi = "10.1038/ncomms7377",
language = "English (US)",
volume = "6",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer

AU - Niederst, Matthew J.

AU - Sequist, Lecia V.

AU - Poirier, John T.

AU - Mermel, Craig H.

AU - Lockerman, Elizabeth L.

AU - Garcia, Angel R.

AU - Katayama, Ryohei

AU - Costa, Carlotta

AU - Ross, Kenneth N.

AU - Moran, Teresa

AU - Howe, Emily

AU - Fulton, Linnea E.

AU - Mulvey, Hillary E.

AU - Bernardo, Lindsay A.

AU - Mohamoud, Farhiya

AU - Miyoshi, Norikatsu

AU - VanderLaan, Paul A.

AU - Costa, Daniel B.

AU - Jänne, Pasi A.

AU - Borger, Darrell R.

AU - Ramaswamy, Sridhar

AU - Shioda, Toshi

AU - Iafrate, Anthony J.

AU - Getz, Gad

AU - Rudin, Charles M.

AU - Mino-Kenudson, Mari

AU - Engelman, Jeffrey A.

PY - 2015

Y1 - 2015

N2 - Tyrosine kinase inhibitors are effective treatments for non-small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations. However, relapse typically occurs after an average of 1 year of continuous treatment. A fundamental histological transformation from NSCLC to small-cell lung cancer (SCLC) is observed in a subset of the resistant cancers, but the molecular changes associated with this transformation remain unknown. Analysis of tumour samples and cell lines derived from resistant EGFR mutant patients revealed that Retinoblastoma (RB) is lost in 100% of these SCLC transformed cases, but rarely in those that remain NSCLC. Further, increased neuroendocrine marker and decreased EGFR expression as well as greater sensitivity to BCL2 family inhibition are observed in resistant SCLC transformed cancers compared with resistant NSCLCs. Together, these findings suggest that this subset of resistant cancers ultimately adopt many of the molecular and phenotypic characteristics of classical SCLC.

AB - Tyrosine kinase inhibitors are effective treatments for non-small-cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) mutations. However, relapse typically occurs after an average of 1 year of continuous treatment. A fundamental histological transformation from NSCLC to small-cell lung cancer (SCLC) is observed in a subset of the resistant cancers, but the molecular changes associated with this transformation remain unknown. Analysis of tumour samples and cell lines derived from resistant EGFR mutant patients revealed that Retinoblastoma (RB) is lost in 100% of these SCLC transformed cases, but rarely in those that remain NSCLC. Further, increased neuroendocrine marker and decreased EGFR expression as well as greater sensitivity to BCL2 family inhibition are observed in resistant SCLC transformed cancers compared with resistant NSCLCs. Together, these findings suggest that this subset of resistant cancers ultimately adopt many of the molecular and phenotypic characteristics of classical SCLC.

UR - http://www.scopus.com/inward/record.url?scp=84924590266&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924590266&partnerID=8YFLogxK

U2 - 10.1038/ncomms7377

DO - 10.1038/ncomms7377

M3 - Article

C2 - 25758528

AN - SCOPUS:84924590266

VL - 6

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 6377

ER -